Exclusive Summary

• Potential First-in-class EGFR/HER2 dual-target ADC, offering a novel mechanism that blocks both homo- and heterodimer signaling.
• Demonstrated remarkable superiority over the blockbuster DS-8201 (Enhertu) in preclinical PDX models across lung, breast, and gastric cancers, highlighting its potential to overcome single-target resistance.
• Features cutting-edge molecular design, including Knobs-into-holes bispecific technology, highly stable/hydrophilic proprietary linkers, and a Topo I payload with a strong bystander effect.
• Broad applicability targeting five major solid tumors (urothelial, colorectal, lung, breast, gastric), currently in Phase 1 trials with an estimated global market potential of $4.3 billion.
• Presents a high-value opportunity for License-out or co-development, enabling overseas MNCs to rapidly establish a foothold in next-generation bispecific ADCs for heterogeneous tumors.

Asset Materials

Contact Us for Full Materials